JP2017530099A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017530099A5 JP2017530099A5 JP2017510495A JP2017510495A JP2017530099A5 JP 2017530099 A5 JP2017530099 A5 JP 2017530099A5 JP 2017510495 A JP2017510495 A JP 2017510495A JP 2017510495 A JP2017510495 A JP 2017510495A JP 2017530099 A5 JP2017530099 A5 JP 2017530099A5
- Authority
- JP
- Japan
- Prior art keywords
- binding domain
- fzd
- signaling agonist
- signaling
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000011664 signaling Effects 0.000 claims description 77
- 239000000556 agonist Substances 0.000 claims description 62
- 108050003627 Wnt Proteins 0.000 claims description 51
- 102000013814 Wnt Human genes 0.000 claims description 51
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 102000015735 Beta-catenin Human genes 0.000 claims description 10
- 108060000903 Beta-catenin Proteins 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 210000001519 tissue Anatomy 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 229920001184 polypeptide Polymers 0.000 claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- 101710181403 Frizzled Proteins 0.000 claims description 6
- 102000005698 Frizzled receptors Human genes 0.000 claims description 6
- 108010045438 Frizzled receptors Proteins 0.000 claims description 6
- 230000006378 damage Effects 0.000 claims description 6
- 230000002708 enhancing effect Effects 0.000 claims description 6
- 239000013642 negative control Substances 0.000 claims description 5
- 230000007935 neutral effect Effects 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 230000029663 wound healing Effects 0.000 claims description 5
- 201000004384 Alopecia Diseases 0.000 claims description 4
- 208000008960 Diabetic foot Diseases 0.000 claims description 4
- 208000001132 Osteoporosis Diseases 0.000 claims description 4
- 108091008324 binding proteins Proteins 0.000 claims description 4
- 102000023732 binding proteins Human genes 0.000 claims description 4
- 230000003676 hair loss Effects 0.000 claims description 4
- 108020003175 receptors Proteins 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims description 4
- 210000005260 human cell Anatomy 0.000 claims description 3
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 claims description 2
- 101100394745 Bacillus subtilis (strain 168) hepT gene Proteins 0.000 claims description 2
- 208000020084 Bone disease Diseases 0.000 claims description 2
- 208000015943 Coeliac disease Diseases 0.000 claims description 2
- 206010012335 Dependence Diseases 0.000 claims description 2
- 208000004930 Fatty Liver Diseases 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 2
- 101000864646 Homo sapiens Dickkopf-related protein 1 Proteins 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 206010028116 Mucosal inflammation Diseases 0.000 claims description 2
- 201000010927 Mucositis Diseases 0.000 claims description 2
- 101100338762 Pedobacter heparinus (strain ATCC 13125 / DSM 2366 / CIP 104194 / JCM 7457 / NBRC 12017 / NCIMB 9290 / NRRL B-14731 / HIM 762-3) hepB gene Proteins 0.000 claims description 2
- 208000031845 Pernicious anaemia Diseases 0.000 claims description 2
- 206010038540 Renal tubular necrosis Diseases 0.000 claims description 2
- 206010049416 Short-bowel syndrome Diseases 0.000 claims description 2
- 206010040844 Skin exfoliation Diseases 0.000 claims description 2
- 208000025865 Ulcer Diseases 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 230000006727 cell loss Effects 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 230000007882 cirrhosis Effects 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 208000016097 disease of metabolism Diseases 0.000 claims description 2
- 210000003027 ear inner Anatomy 0.000 claims description 2
- 208000010706 fatty liver disease Diseases 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 208000024963 hair loss Diseases 0.000 claims description 2
- 102000050762 human DKK1 Human genes 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 210000004153 islets of langerhan Anatomy 0.000 claims description 2
- 210000001503 joint Anatomy 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 210000005084 renal tissue Anatomy 0.000 claims description 2
- 230000001953 sensory effect Effects 0.000 claims description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 231100000397 ulcer Toxicity 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 claims 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 claims 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 claims 2
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 claims 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 claims 2
- 229940126864 fibroblast growth factor Drugs 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- 239000001963 growth medium Substances 0.000 claims 2
- 102000016362 Catenins Human genes 0.000 claims 1
- 108010067316 Catenins Proteins 0.000 claims 1
- 102000007982 Phosphoproteins Human genes 0.000 claims 1
- 108010089430 Phosphoproteins Proteins 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 239000006143 cell culture medium Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 210000002220 organoid Anatomy 0.000 claims 1
- 210000003370 receptor cell Anatomy 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 2
- 102100025036 Norrin Human genes 0.000 description 1
- 101710085992 Norrin Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462049949P | 2014-09-12 | 2014-09-12 | |
| US62/049,949 | 2014-09-12 | ||
| US201562206150P | 2015-08-17 | 2015-08-17 | |
| US62/206,150 | 2015-08-17 | ||
| PCT/US2015/049829 WO2016040895A1 (en) | 2014-09-12 | 2015-09-11 | Wnt signaling agonist molecules |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020138446A Division JP2020186267A (ja) | 2014-09-12 | 2020-08-19 | Ｗｎｔシグナリングアゴニスト分子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017530099A JP2017530099A (ja) | 2017-10-12 |
| JP2017530099A5 true JP2017530099A5 (cg-RX-API-DMAC7.html) | 2018-09-13 |
| JP6796059B2 JP6796059B2 (ja) | 2020-12-02 |
Family
ID=55459641
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017510495A Active JP6796059B2 (ja) | 2014-09-12 | 2015-09-11 | Ｗｎｔシグナリングアゴニスト分子 |
| JP2020138446A Withdrawn JP2020186267A (ja) | 2014-09-12 | 2020-08-19 | Ｗｎｔシグナリングアゴニスト分子 |
| JP2023080152A Pending JP2023091081A (ja) | 2014-09-12 | 2023-05-15 | Ｗｎｔシグナリングアゴニスト分子 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020138446A Withdrawn JP2020186267A (ja) | 2014-09-12 | 2020-08-19 | Ｗｎｔシグナリングアゴニスト分子 |
| JP2023080152A Pending JP2023091081A (ja) | 2014-09-12 | 2023-05-15 | Ｗｎｔシグナリングアゴニスト分子 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US11142577B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4219564A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP6796059B2 (cg-RX-API-DMAC7.html) |
| AU (2) | AU2015314771B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2959045A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016040895A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016040895A1 (en) | 2014-09-12 | 2016-03-17 | xxTHE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | Wnt signaling agonist molecules |
| US20170349659A1 (en) * | 2016-06-03 | 2017-12-07 | The Board Of Trustees Of The Leland Stanford Junior University | Wnt signaling agonist molecules |
| US11993645B2 (en) | 2017-01-11 | 2024-05-28 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions comprising R-Spondin (RSPO) surrogate molecules |
| AU2018211985B2 (en) | 2017-01-26 | 2025-02-13 | Surrozen Operating, Inc. | Tissue-specific Wnt signal enhancing molecules and uses thereof |
| KR101966523B1 (ko) * | 2017-05-29 | 2019-04-05 | 차의과학대학교 산학협력단 | 오가노이드 배양을 위한 조성물 및 방법 |
| EP3731867A4 (en) * | 2017-12-19 | 2022-04-06 | Surrozen Operating, Inc. | Anti-lrp5/6 antibodies and methods of use |
| EP3732201A4 (en) * | 2017-12-19 | 2022-04-20 | Surrozen Operating, Inc. | WNT SURROGATES AND THEIR USES |
| US12006368B2 (en) | 2017-12-19 | 2024-06-11 | Surrozen Operating, Inc. | Anti-frizzled antibodies and methods of use |
| CN111989345A (zh) * | 2018-02-14 | 2020-11-24 | 安托拉诊疗公司 | 激活wnt信号传导的多价结合分子及其用途 |
| WO2019178478A1 (en) | 2018-03-16 | 2019-09-19 | The Board Of Trustees Of The Leland Stanford Junior University | Reagents and methods with wnt agonists and bioactive lipids for generating and expanding cardiomyocytes |
| DK3820906T3 (da) * | 2018-07-05 | 2025-12-15 | Surrozen Operating Inc | Multispecifikke wnt-surrogatmolekyler og anvendelser deraf |
| CN112654363A (zh) | 2018-07-09 | 2021-04-13 | 瑟罗泽恩公司 | 组织特异性wnt信号增强分子和其用途 |
| US12084684B2 (en) | 2018-07-16 | 2024-09-10 | The Board Of Trustees Of The Leland Stanford Junior University | Frizzled specific Wnt agonists and antagonists |
| US20220064337A1 (en) * | 2018-12-19 | 2022-03-03 | Surrozen, Inc. | Antigen binding formats for receptor complexes |
| EP3924381A4 (en) * | 2019-02-11 | 2023-07-26 | Surrozen Operating, Inc. | MODULATION OF WNT SIGNALING IN EYE DISEASES |
| EP3938036A4 (en) * | 2019-03-11 | 2023-06-28 | Surrozen Operating, Inc. | Modulation of wnt signaling in gastrointestinal disorders |
| KR20220024460A (ko) * | 2019-06-11 | 2022-03-03 | 안틀라 테라퓨틱스 아이엔씨. | 다가 fzd 및 wnt 결합 분자 및 이의 용도 |
| EP3789049A1 (en) | 2019-09-06 | 2021-03-10 | QGel SA | Method for obtaining healthy intestinal organoids |
| KR20230109668A (ko) | 2020-11-16 | 2023-07-20 | 서로젠 오퍼레이팅, 인크. | 간-특이적 Wnt 신호 증강 분자 및 그의 용도 |
| US20240150473A1 (en) * | 2021-03-10 | 2024-05-09 | Surrozen Operating, Inc. | Modulation of wnt signaling in gastrointestinal disorders |
| AU2022413699A1 (en) * | 2021-12-17 | 2024-07-04 | Surrozen Operating, Inc. | Wnt-surrogate agents and methods for lacrimal gland regeneration |
| WO2024227103A1 (en) * | 2023-04-27 | 2024-10-31 | Surrozen Operating, Inc. | Molecules modulating wnt signaling pathways and uses thereof |
| WO2024249444A2 (en) * | 2023-05-29 | 2024-12-05 | Surrozen Operating, Inc. | Wnt surrogate agents and methods for lacrimal gland regeneration |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
| EP0773227A1 (en) | 1991-09-18 | 1997-05-14 | Affymax Technologies N.V. | Diverse collections of oligomers in use to prepare drugs, diagnostic reagents, pesticides or herbicides |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| JPH08506175A (ja) | 1992-10-01 | 1996-07-02 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | タグでコードされる複合体の組合せ化学ライブラリー |
| JPH09508353A (ja) | 1993-11-02 | 1997-08-26 | アフィマックス テクノロジーズ ナムローゼ フェンノートシャップ | 分子多様性の合成及びスクリーニング |
| JPH10500112A (ja) | 1994-05-06 | 1998-01-06 | ファーマコピーア，インコーポレイテッド | 組合せ ジヒドロベンゾピラン ライブラリー |
| US5663046A (en) | 1994-06-22 | 1997-09-02 | Pharmacopeia, Inc. | Synthesis of combinatorial libraries |
| US7057017B2 (en) | 1997-04-16 | 2006-06-06 | Millennium Pharmaceuticals, Inc. | Human dickkopf-related protein and nucleic acid molecules and uses therefor |
| EP1267616B1 (en) | 2000-03-31 | 2007-08-08 | The General Hospital Corporation | Methods of increasing hair growth by wnt polypeptide |
| US20030044409A1 (en) | 2001-05-01 | 2003-03-06 | Carson Dennis A. | Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens |
| US8637506B2 (en) | 2003-09-22 | 2014-01-28 | Enzo Biochem, Inc. | Compositions and methods for bone formation and remodeling |
| US8367822B2 (en) | 2003-09-22 | 2013-02-05 | Enzo Therapeutics, Inc. | Compositions and methods for bone formation and remodeling |
| US8461155B2 (en) | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
| US9046537B2 (en) | 2003-09-22 | 2015-06-02 | Enzo Biochem, Inc. | Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain |
| US9052324B2 (en) | 2004-05-19 | 2015-06-09 | Enzo Biochem, Inc. | Compounds and assays for controlling Wnt activity |
| US8343922B2 (en) | 2004-05-19 | 2013-01-01 | Enzo Biochem, Inc. | Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells |
| EP1786837B1 (en) | 2004-08-04 | 2013-05-01 | Amgen Inc., | Antibodies to dkk-1 |
| DE102004050620A1 (de) | 2004-10-13 | 2006-04-20 | Eberhard-Karls-Universität Tübingen | Monoklonaler Antikörper gegen Frizzled-Rezeptoren |
| EP1902318A1 (en) | 2005-05-30 | 2008-03-26 | AstraZeneca AB | Methods for identifying fzd8 modulators and the use of such modulators for treating osteoarthritis |
| DE102005035568A1 (de) | 2005-07-25 | 2007-02-01 | M-Phasys Gmbh | Frizzled 9 als Biomarker für Substrukturen des humanen Gehirns |
| CA2635906A1 (en) * | 2006-02-07 | 2007-08-16 | Wyeth | Materials and methods for identifying agents that modulate norrin. norrin mimetics, and agents identified thereby |
| CN105837690A (zh) | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| EP2044123B1 (en) | 2006-06-21 | 2013-03-13 | Oncotherapy Science, Inc. | Tumor-targeting monoclonal antibodies to fzd10 and uses thereof |
| WO2008134632A1 (en) | 2007-04-26 | 2008-11-06 | President And Fellows Of Harvard College | Wnt ligands involved in blood-brain barrier development and uses therefor |
| EP2567709B1 (en) | 2007-11-02 | 2017-12-27 | Novartis AG | Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (LRP6) |
| EP2220247A4 (en) | 2007-11-16 | 2011-10-26 | Nuvelo Inc | ANTIBODY AGAINST LRP6 |
| WO2010016766A2 (en) | 2008-08-08 | 2010-02-11 | Koninklijke Nederlandse Akademie Van Wetenschappen | Antibodies recognizing endogenous human lgr5 and/or lgr6 |
| CN102149728B (zh) * | 2008-09-10 | 2014-10-15 | 霍夫曼-拉罗奇有限公司 | 抑制眼部血管生成的方法 |
| US7982013B2 (en) | 2008-09-26 | 2011-07-19 | Oncomed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
| EP2412800A1 (en) | 2010-07-29 | 2012-02-01 | Koninklijke Nederlandse Akademie van Wetenschappen | Liver organoid, uses thereof and culture method for obtaining them |
| MX2011008044A (es) | 2009-02-03 | 2012-01-12 | Koninklijke Nederlandse Akademie Van Wetenschappen | Medio de cultivo para celulas madre epiteliales y organoides que comprenden las celulas madre. |
| CA2759233C (en) | 2009-04-27 | 2019-07-16 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| WO2011090762A1 (en) | 2009-12-29 | 2011-07-28 | Emergent Product Development Seattle, Llc | Heterodimer binding proteins and uses thereof |
| AU2011217964B2 (en) | 2010-02-19 | 2016-07-14 | The Board Of Regents Of The University Of Oklahoma | Monoclonal antibodies that inhibit the Wnt signaling pathway and methods of production and use thereof |
| CA2791991A1 (en) | 2010-03-24 | 2011-09-29 | Genentech, Inc. | Anti-lrp6 antibodies |
| AU2011235904B2 (en) | 2010-04-01 | 2015-10-08 | Oncomed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
| CN103237811A (zh) | 2010-05-06 | 2013-08-07 | 诺瓦提斯公司 | 用于治疗性低密度脂蛋白相关蛋白质6(lrp6)多价抗体的组合物及使用方法 |
| ES2659406T3 (es) | 2010-05-06 | 2018-03-15 | Novartis Ag | Composiciones y procedimientos de uso para anticuerpos terapéuticos contra la proteína 6 relacionada con las lipoproteínas de baja densidad (LRP6) |
| SG192182A1 (en) | 2011-01-28 | 2013-08-30 | Univ Leland Stanford Junior | Wnt compositions and methods of use thereof |
| GB201106395D0 (en) | 2011-04-14 | 2011-06-01 | Hubrecht Inst | Compounds |
| ES2666856T3 (es) | 2011-11-04 | 2018-05-08 | Novartis Ag | Proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) - constructos extensores de la vida media |
| HUE033245T2 (hu) | 2011-12-19 | 2017-11-28 | Synimmune Gmbh | Bispecifikus ellenanyag molekula |
| MX2014008157A (es) | 2012-01-18 | 2014-10-06 | Genentech Inc | Anticuerpos anti-lrp5 y metodos de uso. |
| WO2014029752A1 (en) | 2012-08-22 | 2014-02-27 | Glaxo Group Limited | Anti lrp6 antibodies |
| WO2014059068A1 (en) | 2012-10-11 | 2014-04-17 | The Trustees Of The University Of Pennsylvania | Methods for the treatment and prevention of osteoporosis and bone-related disorders |
| AU2014212081A1 (en) | 2013-02-04 | 2015-08-13 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a Wnt pathway inhibitor |
| US10047163B2 (en) | 2013-02-08 | 2018-08-14 | Abbvie Stemcentrx Llc | Multispecific constructs |
| US20150376252A1 (en) * | 2013-02-21 | 2015-12-31 | Van Andel Research Institute | Norrin Mutant Polypeptides, Methods of Making and Uses Thereof |
| JP2016512533A (ja) | 2013-03-14 | 2016-04-28 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Ｍｅｔ結合剤およびその使用 |
| GB2518221A (en) | 2013-09-16 | 2015-03-18 | Sergej Michailovic Kiprijanov | Tetravalent antigen-binding protein molecule |
| GB2519786A (en) | 2013-10-30 | 2015-05-06 | Sergej Michailovic Kiprijanov | Multivalent antigen-binding protein molecules |
| WO2016040895A1 (en) | 2014-09-12 | 2016-03-17 | xxTHE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | Wnt signaling agonist molecules |
| US9777052B2 (en) | 2014-12-02 | 2017-10-03 | The Board Of Regents Of The University Of Oklahoma | R-spondin variants, compositions, and methods of use |
| US20160312207A1 (en) | 2015-04-21 | 2016-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | R-spondin antagonists and methods of treating cancer associated with aberrant activation of wnt signaling |
-
2015
- 2015-09-11 WO PCT/US2015/049829 patent/WO2016040895A1/en not_active Ceased
- 2015-09-11 CA CA2959045A patent/CA2959045A1/en active Pending
- 2015-09-11 JP JP2017510495A patent/JP6796059B2/ja active Active
- 2015-09-11 EP EP23157332.0A patent/EP4219564A1/en not_active Withdrawn
- 2015-09-11 AU AU2015314771A patent/AU2015314771B2/en active Active
- 2015-09-11 US US15/508,779 patent/US11142577B2/en active Active
- 2015-09-11 EP EP15840226.3A patent/EP3191526B1/en active Active
-
2020
- 2020-08-19 JP JP2020138446A patent/JP2020186267A/ja not_active Withdrawn
-
2021
- 2021-05-13 AU AU2021203059A patent/AU2021203059A1/en not_active Abandoned
- 2021-09-08 US US17/469,661 patent/US20210403578A1/en not_active Abandoned
-
2023
- 2023-05-15 JP JP2023080152A patent/JP2023091081A/ja active Pending
-
2024
- 2024-04-04 US US18/627,108 patent/US20250011437A1/en not_active Abandoned
-
2025
- 2025-03-03 US US19/069,060 patent/US20250304702A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017530099A5 (cg-RX-API-DMAC7.html) | ||
| Chan et al. | Matrix‐bound vegf mimetic peptides: design and endothelial‐cell activation in collagen scaffolds | |
| ES2585702T3 (es) | Composiciones y métodos para la unión al ácido lisofosfatídico | |
| PE20250757A1 (es) | Muteinas de interleucina 21 y metodos de tratamiento | |
| Wilson et al. | Stoichiometric post‐modification of hydrogel microparticles dictates neural stem cell fate in microporous annealed particle scaffolds | |
| MX2021014601A (es) | Proteinas recombinantes de union a fap y su uso. | |
| NO20083793L (no) | Antistoffer mot amyloid-beta peptid | |
| JP2012511545A5 (cg-RX-API-DMAC7.html) | ||
| PE20091405A1 (es) | Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf | |
| DK2343320T3 (da) | Anti-gitr-antistoffer og anvendelser deraf | |
| JP2017000143A5 (cg-RX-API-DMAC7.html) | ||
| Stahl et al. | Capillary network‐like organization of endothelial cells in PEGDA scaffolds encoded with angiogenic signals via triple helical hybridization | |
| DE602005019064D1 (de) | Verfahren zur herstellung gefriergetrockneter blutplättchen, gefriergetrocknete blutplättchen enthaltende zusammensetzungen und verwendungsverfahren | |
| CY1118389T1 (el) | Νεα αντισωματα ανταγωνιστων και fab θραυσματα αυτων εναντι του gpvi και χρησεις αυτων | |
| JP2017507670A5 (cg-RX-API-DMAC7.html) | ||
| MX2009009226A (es) | Anticuerpos recombinantes para el tratamiento de infecciones con el virus respiratorio sincitial. | |
| MEP53308A (en) | Novel peptides that bind to the erythropoietin receptor | |
| UA97516C2 (ru) | Полностью человеческое моноклональное антитело против vap-1 | |
| ATE485517T1 (de) | Verfahren zur identifizierung von polypeptid- targets | |
| MX2023010365A (es) | Proteina liofilizada estable a temperatura ambiente. | |
| RU2018108421A (ru) | Рекомбинантные белки и их применения в терапевтических целях | |
| NZ749578A (en) | Anti-met antibodies and uses thereof | |
| JP2010501594A5 (cg-RX-API-DMAC7.html) | ||
| JP2018512124A5 (cg-RX-API-DMAC7.html) | ||
| BRPI0607883A2 (pt) | método para obter material celular prontamente disponìvel derivado de sangue periférico e uma composição do referido material celular |